The global exocrine pancreatic insufficiency therapeutics market to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period. Increasing prevalence of diabetes worldwide is touted to be one of the core factors fueling the growth of this market. According to the International Diabetes Federation (IDF), in 2019, approximately 463 million adults were suffering from diabetes and by 2045, this figure will rise to 700 million.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/exocrine-pancreatic-insufficiency-market-100652
Table of Content from Exocrine Pancreatic Insufficiency Therapeutics Market:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
4.2. Pipeline Analysis
4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
4.4. Regulatory Scenario
4.5. New Product Launches
- Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Therapy
5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
5.2.1.1. Creon
5.2.1.2. Zenpep
5.2.1.3. Others
5.2.2. Nutritional Therapy
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies & Drug Stores
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Country
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Rest of the World
- North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Therapy
6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
6.2.1.1. Creon
6.2.1.2. Zenpep
6.2.1.3. Others
6.2.2. Nutritional Therapy
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies & Drug Stores
6.3.3. Others
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.2. Canada
TOC Continued…..
The global exocrine pancreatic insufficiency therapeutics market to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period.
In the same year, the disease caused deaths of 4.2 million people and around 374 million people are at an increased risk of developing type 2 diabetes.
We understand that this health crisis has brought an unprecedented impact on businesses across industries.
Rising support from governments and several companies can help in the fight against this highly contagious disease.
Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics.
Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.Click here to get the short-term and long-term impact of COVID-19 on this [Market].For More Information : https://www.fortunebusinessinsights.com/industry-reports/exocrine-pancreatic-insufficiency-market-100652According the new Fortune Business Insights report, titled “Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share & Industry Analysis, By Therapy (Pancreatic Enzyme Replacement Therapy (PERT), Nutritional Therapy), By Distribution Channel (Hospital Pharmacies ,Retail Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026”, the value of the market stood at USD 1.49 billion in 2018.
